BL-0020 is under clinical development by Shanghai Best-Link Bioscience and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData, Phase I drugs for Small-Cell Lung Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BL-0020’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BL-0020 overview

BL-0020 is under development for the treatment of solid tumors including triple-negative breast cancer, small cell lung cancer, pancreatic cancer and unspecified indication. The therapeutic candidate is administered through intravenous route.

Shanghai Best-Link Bioscience overview

Shanghai Best-Link Bioscience a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for the treatment of cancer and autoimmune diseases. The company is headquartered in Shanghai City, Shanghai, China.

For a complete picture of BL-0020’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 1 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.